Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
Spruce Biosciences (Nasdaq: SPRB), a late-stage biopharmaceutical company specializing in novel therapies for endocrine and neurological disorders, has announced its participation in the Guggenheim Securities Healthcare Innovation Conference. The company's CEO, Javier Szwarcberg, M.D., M.P.H., will deliver a presentation on November 11, 2024, at 3:30 p.m. ET. The presentation will be accessible via live webcast, with a recording available on the company's investor relations website for approximately 90 days following the event.
Spruce Biosciences (Nasdaq: SPRB), un'azienda biofarmaceutica in fase avanzata specializzata in terapie innovative per disturbi endocrini e neurologici, ha annunciato la sua partecipazione alla Guggenheim Securities Healthcare Innovation Conference. Il CEO dell'azienda, Javier Szwarcberg, M.D., M.P.H., presenterà il suo intervento l'11 novembre 2024, alle 15:30 ET. La presentazione sarà accessibile tramite webcast dal vivo, con una registrazione disponibile sul sito web delle relazioni con gli investitori dell'azienda per circa 90 giorni dopo l'evento.
Spruce Biosciences (Nasdaq: SPRB), una compañía biofarmacéutica en etapa avanzada que se especializa en terapias novedosas para trastornos endocrinos y neurológicos, ha anunciado su participación en la Guggenheim Securities Healthcare Innovation Conference. El CEO de la compañía, Javier Szwarcberg, M.D., M.P.H., realizará una presentación el 11 de noviembre de 2024 a las 3:30 p.m. ET. La presentación estará disponible a través de un webcast en vivo, con una grabación accesible en el sitio web de relaciones con inversores de la compañía durante aproximadamente 90 días después del evento.
Spruce Biosciences (Nasdaq: SPRB)은 내분비 및 신경 장애를 위한 혁신적인 치료법을 전문으로 하는 말기 단계의 생명공학 회사로, 구겐하임 증권 의료 혁신 컨퍼런스에 참가한다고 발표했습니다. 회사의 CEO인 Javier Szwarcberg, M.D., M.P.H.는 2024년 11월 11일 오후 3시 30분(ET)에 발표를 진행할 예정입니다. 발표는 라이브 웹캐스트를 통해 시청할 수 있으며, 행사 후 약 90일 동안 회사의 투자자 관계 웹사이트에서 기록 영상을 이용할 수 있습니다.
Spruce Biosciences (Nasdaq: SPRB), une entreprise biopharmaceutique en phase avancée spécialisée dans les thérapies novatrices pour les troubles endocriniens et neurologiques, a annoncé sa participation à la Guggenheim Securities Healthcare Innovation Conference. Le PDG de l'entreprise, Javier Szwarcberg, M.D., M.P.H., fera une présentation le 11 novembre 2024 à 15h30 ET. La présentation sera accessible via un webcast en direct, avec un enregistrement disponible sur le site web des relations investisseurs de l'entreprise pendant environ 90 jours après l'événement.
Spruce Biosciences (Nasdaq: SPRB), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf neuartige Therapien für endokrine und neurologische Störungen spezialisiert hat, hat seine Teilnahme an der Guggenheim Securities Healthcare Innovation Conference angekündigt. Der CEO des Unternehmens, Javier Szwarcberg, M.D., M.P.H., wird am 11. November 2024 um 15:30 Uhr ET eine Präsentation halten. Die Präsentation wird über einen Live-Webcast verfügbar sein, mit einer Aufzeichnung, die etwa 90 Tage nach der Veranstaltung auf der Investor-Relations-Website des Unternehmens zur Verfügung steht.
- None.
- None.
Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 90 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need. Spruce is developing its product candidate, tildacerfont, an oral, second-generation CRF1 receptor antagonist, for the treatment of congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS) and major depressive disorder (MDD). To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028643351/en/
Media
Katie Beach Oltsik
Inizio Evoke Comms
(937) 232-4889
Katherine.Beach@inizioevoke.com
media@sprucebio.com
Investors
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
investors@sprucebio.com
Source: Spruce Biosciences, Inc.
FAQ
When is Spruce Biosciences (SPRB) presenting at the Guggenheim Securities Healthcare Conference?
How long will Spruce Biosciences' (SPRB) Guggenheim Conference webcast be available?
What is Spruce Biosciences' (SPRB) main business focus?
Who will represent Spruce Biosciences (SPRB) at the Guggenheim Healthcare Conference?
